Viemed Healthcare Announces Acquisition of Lehan Drugs

Viemed Healthcare ( (VMD) ) has issued an announcement.

On May 6, 2025, Viemed Healthcare announced its definitive agreement to acquire Lehan Drugs, Inc., a provider of home medical equipment based in Illinois, for $26 million. This strategic acquisition, expected to close in the third quarter of 2025, aims to diversify Viemed’s product offerings into maternal health and expand its market presence, leveraging Lehan’s established reputation and community engagement in the healthcare sector.

Spark’s Take on VMD Stock

According to Spark, TipRanks’ AI Analyst, VMD is a Outperform.

Viemed Healthcare demonstrates strong financial growth, particularly in revenue and gross margins, but faces challenges with declining net margins and free cash flow volatility. Technical indicators are bearish, hinting at potential short-term pressure. However, the company’s strong guidance and strategic growth plans provide a positive outlook, supporting a balanced overall score.

To see Spark’s full report on VMD stock, click here.

More about Viemed Healthcare

Viemed Healthcare, Inc. is an in-home clinical care provider specializing in post-acute respiratory healthcare equipment and services in the United States. The company offers non-invasive ventilators, sleep therapy, staffing, and other complementary products and services, focusing on efficient in-home treatment with clinical practitioners providing therapy, education, and counseling to patients.

Average Trading Volume: 118,283

Technical Sentiment Signal: Sell

Current Market Cap: $291.3M

See more data about VMD stock on TipRanks’ Stock Analysis page.